Group 1 - The A-share and Hong Kong stock indices collectively declined on May 28, with the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index experiencing a slight pullback [1] - The Tianhong Innovative Drug ETF (517380) showed fluctuating performance, with a premium rate of 0.33% as of the report, and several constituent stocks such as Ganli Pharmaceutical and Heng Rui Medicine saw gains [1] - As of May 27, the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index has increased by 15.61% since the beginning of the year [1] Group 2 - Pacific Securities emphasizes the importance of the pharmaceutical sector due to changes in market pricing power and suggests a strategic focus on AI healthcare and innovative drugs [2] - Guotai Junan Securities notes that several domestic innovative drug research projects have been selected for the 2025 ASCO conference, indicating a robust trend in domestic pharmaceutical R&D, particularly in cancer treatment [2]
创新药ETF天弘（517380）盘中溢价，其跟踪指数年内涨超15%，机构：重视医药板块增量影响
2 1 Shi Ji Jing Ji Bao Dao·2025-05-28 03:01